1258458-26-2Relevant academic research and scientific papers
Studies of anti-HIV transcription inhibitor quinolones: Identification of potent N1-vinyl derivatives
Tabarrini, Oriana,Massari, Serena,Daelemans, Dirk,Meschini, Francesco,Manfroni, Giuseppe,Bottega, Laura,Gatto, Barbara,Palumbo, Manlio,Pannecouque, Christophe,Cecchetti, Violetta
, p. 1880 - 1892 (2010)
The 6-desfluoroquinolones (6-DFQs) are anti-HIV agents that target Tat-mediated transcription. This particular mechanism of action makes this class of compounds very attractive for further structural investigations. Identification of the pharmacophore req
Ethyl 1,8-naphthyridone-3-carboxylates downregulate human papillomavirus-16 E6 and E7 oncogene expression
Donalisio, Manuela,Massari, Serena,Argenziano, Monica,Manfroni, Giuseppe,Cagno, Valeria,Civra, Andrea,Sabatini, Stefano,Cecchetti, Violetta,Loregian, Arianna,Cavalli, Roberta,Lembo, David,Tabarrini, Oriana
supporting information, p. 5649 - 5663 (2014/08/05)
Strong epidemiological and molecular data associate cervical cancer (CC) with high-risk human papillomavirus (HPV) infections. The carcinogenic mechanism depends mainly on the expression of E6 and E7 oncoproteins encoded by the viral genome. Using a cell-based high-throughput assay, an in-house library of compounds was screened identifying the 1,8-naphthyridone 1 that efficiently inhibited the transcription driven by the long control region of the HPV genome. A series of analogues were then synthesized, obtaining more potent derivatives able to downregulate E6 and E7 transcripts in HPV-16-positive CC CaSki cells. An unusual structural insight emerged for the C-3 position of the 1,8-naphthyridone core, where the ethyl carboxylate esters, but not the carboxylic acids, are responsible for the activity. In vitro uptake studies showed that the 3-ethyl carboxylates do not act as prodrugs. The 1,8-naphthyridones emerged as valid starting points for the development of innovative agents potentially useful for the treatment of HPV-induced CC.
